Statement Of Cash Flows

Cyfuse Biomedical K.K. - Filing #7272238

Concept As at
2024-12-31
2024-01-01 to
2024-12-31
2023-01-01 to
2023-12-31
As at
2023-12-31
As at
2022-12-31
Statement of cash flows
Statement of cash flows
Cash flows from operating activities
Profit (loss) before income taxes
-869,747,000 JPY
-586,187,000 JPY
Depreciation
36,017,000 JPY
38,122,000 JPY
Interest expenses
9,514,000 JPY
9,774,000 JPY
Decrease (increase) in trade receivables
-3,820,000 JPY
-3,535,000 JPY
Decrease (increase) in inventories
-9,541,000 JPY
-5,646,000 JPY
Increase (decrease) in trade payables
14,295,000 JPY
-1,918,000 JPY
Subtotal
-794,017,000 JPY
-678,354,000 JPY
Income taxes paid
-2,542,000 JPY
-2,441,000 JPY
Other, net
2,284,000 JPY
-16,629,000 JPY
Net cash provided by (used in) operating activities
-760,553,000 JPY
-562,296,000 JPY
Interest paid
-9,941,000 JPY
-9,735,000 JPY
Cash flows from operating activities
Increase (decrease) in accounts payable - other
12,666,000 JPY
-13,246,000 JPY
Cash flows from operating activities
Cash flows from investing activities
Purchase of property, plant and equipment
-7,612,000 JPY
-19,474,000 JPY
Net cash provided by (used in) investing activities
-8,637,000 JPY
-19,474,000 JPY
Cash flows from facilities maintenance and investing activities
Cash flows from financing activities
Proceeds from issuance of shares
16,190,000 JPY
22,880,000 JPY
Repayments of long-term borrowings
-18,000,000 JPY
-77,824,000 JPY
Net cash provided by (used in) financing activities
-52,012,000 JPY
18,236,000 JPY
Net increase (decrease) in cash and cash equivalents
-821,203,000 JPY
-563,534,000 JPY
Cash and cash equivalents
2,052,570,000 JPY
2,873,773,000 JPY
3,437,307,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.